c-MET inhibitor is a targeted therapy that specifically inhibits the activity of the c-MET receptor, a protein involved in cell growth, survival, and metastasis. The mechanism of action of c-MET inhibitors involves blocking the activation of c-MET and downstream signaling pathways, thereby inhibiting tumor growth, angiogenesis, and metastasis. These inhibitors are used in the treatment of various disease indications, including lung cancer, liver cancer, gastric cancer, and colorectal cancer, where aberrant c-MET signaling is implicated in tumor progression. According to the World Health Organization (WHO), lung cancer is one of the leading causes of cancer-related deaths worldwide. In Europe, it is estimated that there were 470,000 new cases of lung cancer in 2020, with approximately 400,000 deaths. In the United States, the American Cancer Society reported that lung cancer accounted for about 11% of all new cancer cases in 2020, with around 135,000 deaths. Liver cancer is another significant indication where c-MET inhibitors show potential. According to the WHO, liver cancer is the sixth most common cancer globally, with about 905,000 new cases and 830,000 deaths reported in 2020. Gastric cancer is prevalent in Europe, with approximately 160,000 new cases reported annually, as stated by the European Society for Medical Oncology (ESMO). Colorectal cancer is a significant burden in the United States, with the National Cancer Institute estimating around 149,500 new cases and 52,980 deaths in 2020.
The growth of the c-MET inhibitor market is driven by several factors, including the increasing prevalence of cancer, advancements in molecular biology and personalized medicine, and ongoing research and development efforts. These factors contribute to a growing demand for targeted therapies like c-MET inhibitors, as they offer the potential for improved patient outcomes and enhanced treatment options. Companies such as J&J, Exelixis, Amgen, BMS, Eli Lilly, Sino Biopharm, Betta Pharma, Merck (MSD), Ipsen, Simcere, Takeda, Daiichi Sankyo, DeuterOncology, EMD Serono, Mirati, Octimet, Otsuka, Pfizer, Roche, Servier, and AbbVie cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, Roche is one such company that is currently conducting a clinical trial of the drug Onartuzumab (RG3638) for the treatment of lung neoplasms.
Key Developments
- In Feb 2021, Istituto Clinico Humanitas completed a phase I/Ib trial of Tivantinib in mesothelioma and non-small cell lung cancer (combination therapy, late-stage disease, first-line therapy, metastatic disease) in Italy
- In January 2020, Merck & co. has acquired the originator of Tivatinib, ArQule
Approved c-MET Inhibitor molecules
- Cabometyx (cabozantinib tablet)
- Xalkori (crizotinib)
- Cometriq (cabozantinib capsule)
- Tabrecta (capmatinib)
- Orpathys (savolitinib)
- Ensacove (ensartinib)
- Tepmetko (tepotinib)
- Rybrevant (amivantamab-vmjw)
- Amivantamab SC (Ami-LC)
c-MET Inhibitor Pipeline Molecules
- Tivantinib (ARQ 197)
- Sitravatinib (MGCD516)
- Onartuzumab (RG3638)
- Rilotumumab (AMG 102)
- Ficlatuzumab (AV-299)
- Foretinib (GSK1363089)
- Merestinib (LY2801653)
- Bozitinib (APL-101)
- Golvatinib (E7050)
- AL2846
- Glesatinib (MGCD265)
- Ningetinib (CT053PTSA)
- AMG 337
- Emibetuzumab (LY2875358)
- Gumarontinib (SCC244)
- HS-10241
- Envonalkib (TQ-B3139)
- Unecritinib (TQ-B3101)
- Zanzalintinib (XL092)
- ABN401
- Amuvatinib (MP470)
- SAR 125844
- Bafisontamab (EMB-01)
- Oremepermin alfa (KP-100)
- AMG 208
- ASLAN002
- BPI-9016M
- CKD-702
- DO-1
- MCLA-129
- MK-2461
- MRX34
- SGX523
- Kanitinib (CX1003)
- Metatinib tromethamine (BMS-794833)
- ARGX-111
- ASKC202
- DO-2
- EMD 1204831
- GB263T
- GST-HG16
- HLX55
- HQP8361
- JNJ-38877605
- PF-04217903
- REGN5093
- RXDX-106
- S-49076
- S95027
- SAIT301
- SPH 3348
- TAK-701
- TAVO412
- TSN084
- Altiratinib (DCC-2701)
- Elzovantinib (TPX-0022)
- Human recombinant dHGF (CSB-001)
- Metatinib trometamol (BMS-817378)
- Pamufetinib (TAS-115)
- Telisotuzumab (h224G11)
Clinical Activity and Development of c-MET Inhibitor
- In the c-MET Inhibitor space, more than 50 companies are conducting more than 500 clinical trials in this category of drugs. For instance,
- In June 2020, Merck & Co. presented pharmacodynamics data from preclinical studies of Tivantinib in non-small cell lung cancer at the 111th annual meeting of the American Association for Cancer Research - II (AACR-2020)
- In April 2023, AstraZeneca and PAREXEL initiated a pharmacokinetics phase I trial (In healthy volunteers) of Orpathys in Germany
|
Product Name |
Total Studies |
|
Tivantinib (ARQ 197) |
50 |
|
Sitravatinib (MGCD516) |
37 |
|
Onartuzumab (RG3638) |
17 |
|
Rilotumumab (AMG 102) |
17 |
|
Ficlatuzumab (AV-299) |
12 |
|
Foretinib (GSK1363089) |
11 |
|
Merestinib (LY2801653) |
11 |
|
Bozitinib (APL-101) |
8 |
|
Golvatinib (E7050) |
8 |
|
AL2846 |
7 |
|
Glesatinib (MGCD265) |
7 |
|
Ningetinib (CT053PTSA) |
7 |
|
AMG 337 |
6 |
|
Emibetuzumab (LY2875358) |
6 |
|
Gumarontinib (SCC244) |
6 |
|
HS-10241 |
5 |
|
Envonalkib (TQ-B3139) |
5 |
|
Unecritinib (TQ-B3101) |
5 |
|
Zanzalintinib (XL092) |
5 |
|
ABN401 |
4 |
Target Indication Analysis of c-MET Inhibitor
c-MET inhibitors are targeted therapies designed to inhibit the activity of the c-MET receptor, a protein involved in cell growth, survival, and metastasis. These inhibitors have shown promise as potential treatments for various types of cancers, including lung, liver, gastric, and colorectal cancers, where aberrant c-MET signaling is implicated in tumor progression. By blocking the activation of c-MET and downstream signaling pathways, c-MET inhibitors aim to inhibit tumor growth, angiogenesis, and metastasis. Additionally, they may enhance the effectiveness of other cancer therapies. Clinical trials are underway to evaluate the efficacy and safety of c-MET inhibitors in different patient populations, with the goal of improving treatment outcomes and expanding treatment options for cancer patients.
Regional Analysis of c-MET Inhibitor
c-MET Inhibitor Market
The global c-MET Inhibitor market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The overall US market analysis of c-MET inhibitors indicates a promising landscape for these targeted therapies. The United States has a well-established healthcare infrastructure and a robust oncology market, making it a key region for the development and commercialization of c-MET inhibitors. The presence of a large patient population affected by various types of cancers, such as lung, liver, and gastric cancers, creates a significant market opportunity. Additionally, the US regulatory environment and favorable reimbursement policies further support market growth for c-MET inhibitors. Several growth drivers are contributing to the expansion of the c-MET inhibitor market. Firstly, the increasing prevalence of cancer in the United States, coupled with the growing understanding of the role of c-MET signaling in tumor progression, creates a strong demand for targeted therapies like c-MET inhibitors. Secondly, advancements in molecular biology and personalized medicine have enabled better patient stratification and identification of those who may benefit from c-MET inhibitors. This precision medicine approach enhances the potential for higher response rates and improved patient outcomes. Furthermore, ongoing research and development efforts in the field, including the exploration of combination therapies and novel drug formulations, are expected to drive market growth by expanding the therapeutic potential of c-MET inhibitors. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for c-MET Inhibitors. These countries are increasingly adopting c-MET Inhibitors due to their efficacy and potential to improve patient outcomes. On the other hand, the c-MET Inhibitor market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the c-MET Inhibitor market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
c-MET Inhibitors drugs are used in the management of lung cancer, liver cancer, gastric cancer, and colorectal cancer, where aberrant c-MET signaling is implicated in tumor progression.
The growth of the c-MET inhibitor market is driven by several factors, including the increasing prevalence of cancer, advancements in molecular biology and personalized medicine, and ongoing research and development efforts.
The major players in this space are J&J, Exelixis, Amgen, BMS, Eli Lilly, Sino Biopharm, Betta Pharma, Merck (MSD), Ipsen, Simcere, Takeda, Daiichi Sankyo, DeuterOncology, EMD Serono, Mirati, Octimet, Otsuka, Pfizer, Roche, Servier, and AbbVie.
The c-MET inhibitor market faces significant restraints due to challenges in drug development, including limited efficacy and safety concerns associated with the inhibition of c-MET signaling pathways. Additionally, the presence of alternative treatment options and competition from other targeted therapies further restricts the growth potential of the c-MET inhibitor market.
- J&J
- Exelixis
- Amgen
- BMS
- Eli Lilly
- Sino Biopharm
- Betta Pharma
- Merck (MSD)
- Ipsen
- Simcere
- Takeda
- Daiichi Sankyo
- DeuterOncology
- EMD Serono
- Mirati
- Octimet
- Otsuka
- Pfizer
- Roche
- Servier
- AbbVie
- Abion
- Advenchen
- Allist
- Aosaikang Pharma
- Apollomics
- Ascentage Pharma
- AstraZeneca
- Avistone Biotech
- BeiGene
- Biodesix
- Chong Kun Dang
- Claris Biotherap
- Deciphera
- Eisai
- EpimAb Biotherap
- Fosun Pharma
- Fujian Cosunter
- Galaxy Biotech
- Genmab
- HEC Pharm
- HaiHe Biopharma
- Hutchmed
- ImmunityBio
- Incyte
- Innovent Biologics
- Jiangsu Hansoh Pharma
- Konruns Pharma
- Kringle
- Kyowa Kirin
- LG Chem
- Ligand
- Merus
- Novartis
- Pierre Fabre
- Regeneron
- Samsung
- Sanofi
- Shanghai Pharma
- Shouyao Holdings
- Synlogic
- Tavotek
- Tyligand
- Walvax
- WuXi AppTec
- Xcovery
- ZAI Lab
- Argenx